Piper Sandler Maintains Buy on ADMA Biologics, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Anthony Petrone maintains a Buy rating on ADMA Biologics and raises the price target from $9 to $10.
March 01, 2024 | 2:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler maintains a Buy rating on ADMA Biologics and increases the price target from $9 to $10.
The upgrade in price target by a reputable analyst like Anthony Petrone signals a strong confidence in ADMA Biologics' future performance. This is likely to positively influence investor sentiment and potentially increase the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100